SSSophia M. Shi

Sophia M. Shi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sophia M. Shi has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mucin-binding protein shuttles enable delivery of brain-targeted therapeutics

    by Sophia M. Shi, Gabrielle S. Tender, Jian Xiong, Josephine K. Buff, Hannah I. Park, Justin H. Mendiola, Edward N. Wilson, Monther Abu-Remaileh, Carolyn R. Bertozzi, Tony Wyss-Coray

    The blood-brain barrier (BBB) poses a major obstacle to the delivery of therapeutics into the central nervous system (CNS) due to its highly restrictive permeability. Here, we introduce glycan-targeted delivery vehicles, or GlycoShuttles, that traverse the BBB by harnessing the cerebrovascular glycocalyx, a carbohydrate-rich layer lining the BBB lumen. We discover that mucin-domain glycoproteins within this structure serve as novel entry portals for brain delivery and engineer mucin-binding protein shuttles that enable efficient transport of diverse molecular cargo across the BBB into multiple key brain cell types. This modular platform facilitates enhanced brain delivery of a variety of payloads, including antibodies and lysosomal proteins, and demonstrates therapeutic efficacy in mouse models of dementia. Our findings establish mucin-targeted GlycoShuttles as a versatile platform for noninvasive brain delivery of therapeutics, opening new avenues for the treatment of CNS diseases.

  • Top Cited Papers
    Open Access

    Ageing promotes microglial accumulation of slow-degrading synaptic proteins

    by Ian H. Guldner, Viktoria P. Wagner, Patricia Moran-Losada, Sophia M. Shi, Sophia W. Golub, Johannes F. Hevler, Kelly Chen, Barbara T. Meese, Ali Ghoochani, Ernst Pulido, et al.

    Neurodegenerative diseases affect 1 in 12 people globally and remain incurable. Central to their pathogenesis is a loss of neuronal protein maintenance and the accumulation of protein aggregates with ageing1,2. Here we engineered bioorthogonal tools3 that enabled us to tag the nascent neuronal proteome and study its turnover with ageing, its propensity to aggregate and its interaction with microglia. We show that neuronal protein half-life approximately doubles on average between 4-month-old and 24-month-old mice, with the stability of individual proteins differing among brain regions. Furthermore, we describe the aged neuronal ‘aggregome’, which encompasses 1,726 proteins, nearly half of which show reduced degradation with age. The aggregome includes well-known proteins linked to diseases and numerous proteins previously not associated with neurodegeneration. Notably, we demonstrate that neuronal proteins accumulate in aged microglia, with 54% also displaying reduced degradation and/or aggregation with age. Among these proteins, synaptic proteins are highly enriched, which suggests that there is a cascade of events that emerge from impaired synaptic protein turnover and aggregation to the disposal of these proteins, possibly through microglial engulfment of synapses. These findings reveal the substantial loss of neuronal proteome maintenance with ageing, which could be causal for age-related synapse loss and cognitive decline.


  • Open Access

    Age-related microbiome metabolites alter RNA splicing and chromatin accessibility in the brain

    by Meenakshi Chakraborty, Sophia M. Shi, Imani E. Porter, Daniel J. Richard, Georgi K. Marinov, Ashley A. Moore, Jenna L. E. Blum, Aravind Natarajan, James W. Jahng, Joseph C. Wu, et al.

    The gut microbiome generates diverse metabolites that can enter the bloodstream and alter host biology, including brain function. Hundreds of physiologically relevant, gut-brain signaling molecules likely exist; however, there has been no systematic, high-throughput effort to identify and validate them. Here, we integrate computational, in vitro , and in vivo approaches to pinpoint microbiome-derived metabolites whose blood levels change during aging, and that induce corresponding changes in the mouse brain. First, we mine large-scale metabolomics datasets from human cohorts (each n ≥ 1200) to identify 30 microbiome-associated metabolites whose blood levels change with age. We then screen this panel in an in vitro transcriptomic assay to identify metabolites that perturb genes linked to age-related neurodegeneration. We then test four metabolites in an acute-exposure mouse model, and use multi-omic approaches to evaluate their impact on cellular functions in the brain. We confirm the known neurodegeneration-promoting effects of trimethylamine N-oxide (TMAO), including mitochondrial dysfunction, and further discover its disruptive impact on the pathways of glycolysis, GABAergic signaling, and RNA splicing. Additionally, we identify glycodeoxycholic acid (GDCA), a microbiome-derived secondary bile acid, as a potent regulator of chromatin accessibility and suppressor of genes that protect the brain from age-related, neurodegeneration-promoting insults. GDCA also acutely reduces mobility. In summary, we present a scalable framework for linking microbiome metabolites to host pathologies, and apply it to identify microbial metabolites that induce molecular changes related to neurodegeneration.


  • Open Access

    Sophia Shi: Decoding the role of sugar molecules in brain aging and neurodegenerative diseases

    by Sophia M. Shi

    Stanford Chemistry PhD graduate Sophia Shi reveals her pioneering journey decoding how sugar molecules protect aging brains in this Genomic Press Interview. Working under the mentorship of Nobel laureate Carolyn Bertozzi and renowned neurobiologist Tony Wyss-Coray, Dr. Shi has uncovered groundbreaking evidence that the brain's protective glycocalyx, a complex sugar coating on blood-brain barrier endothelial cells, deteriorates dramatically with age, contributing to cognitive decline and neurodegenerative diseases. Her recent Nature publication demonstrates that this “forest” of sugar molecules becomes sparse and degraded in aging brains, leading to blood-brain barrier dysfunction and neuroinflammation. Remarkably, her team demonstrated that restoring these critical mucin-type O-glycans in aged mice significantly improves barrier integrity and cognitive function, thereby opening up unprecedented therapeutic avenues for Alzheimer's disease and related conditions. Now launching her independent laboratory at Harvard's prestigious Rowland Institute directly from doctoral training, a rare achievement that speaks to her exceptional promise, Dr. Shi represents a new generation of interdisciplinary scientists seamlessly bridging glycobiology and neuroscience. From solving childhood puzzles in New Jersey to decoding molecular mysteries at Stanford, she shares candid insights on navigating scientific challenges, the transformative impact of supportive mentorship, building inclusive research environments, and her ambitious vision for developing glycan-based therapies to combat brain aging. Her recognition with the David S. Miller Young Scientist Award at the Cerebral Vascular Biology Conference underscores her emergence as a leading voice in understanding how post-translational modifications, particularly glycosylation, shape brain health, and resilience throughout the lifespan, offering tangible hope for millions affected by age-related cognitive decline and neurodegenerative diseases worldwide.

  • Top Cited Papers
    Open Access

    Glycocalyx dysregulation impairs blood–brain barrier in ageing and disease

    by Sophia M. Shi, Ryan J. Suh, D. Judy Shon, Francisco J. Garcia, Josephine K. Buff, Micaiah Atkins, Lulin Li, Nannan Lu, Bryan Sun, Jian Luo, et al.

    The blood–brain barrier (BBB) is highly specialized to protect the brain from harmful circulating factors in the blood and maintain brain homeostasis1,2. The brain endothelial glycocalyx layer, a carbohydrate-rich meshwork composed primarily of proteoglycans, glycoproteins and glycolipids that coats the BBB lumen, is a key structural component of the BBB3,4. This layer forms the first interface between the blood and brain vasculature, yet little is known about its composition and roles in supporting BBB function in homeostatic and diseased states. Here we find that the brain endothelial glycocalyx is highly dysregulated during ageing and neurodegenerative disease. We identify significant perturbation in an underexplored class of densely O-glycosylated proteins known as mucin-domain glycoproteins. We demonstrate that ageing- and disease-associated aberrations in brain endothelial mucin-domain glycoproteins lead to dysregulated BBB function and, in severe cases, brain haemorrhaging in mice. Finally, we demonstrate that we can improve BBB function and reduce neuroinflammation and cognitive deficits in aged mice by restoring core 1 mucin-type O-glycans to the brain endothelium using adeno-associated viruses. Cumulatively, our findings provide a detailed compositional and structural mapping of the ageing brain endothelial glycocalyx layer and reveal important consequences of ageing- and disease-associated glycocalyx dysregulation on BBB integrity and brain health.


  • Open Access

    Luminal Cerebrovascular Proteomics

    by Sophia M. Shi, Carolyn R. Bertozzi, Tony Wyss-Coray

    Brain endothelial cells, which constitute the cerebrovasculature, form the first interface between the blood and brain and play essential roles in maintaining central nervous system (CNS) homeostasis. These cells exhibit strong apicobasal polarity, with distinct luminal and abluminal membrane compositions that crucially mediate compartmentalized functions of the vasculature. Existing transcriptomic and proteomic profiling techniques often lack the spatial resolution to discriminate between these membrane compartments, limiting insights into their distinct molecular compositions and functions. To overcome these limitations, we developed an in vivo proteomic strategy to selectively label and enrich luminal cerebrovascular proteins. In this approach, we perfuse a membrane-impermeable biotinylation reagent into the vasculature to covalently tag cell surface proteins exposed on the luminal side. This is followed by microvessel isolation and streptavidin-based enrichment of biotinylated proteins for downstream mass spectrometry analysis. Using this method, we robustly identified over 1,000 luminally localized proteins via standard liquid chromatography–tandem mass spectrometry (LC–MS/MS) techniques, achieving substantially improved enrichment of canonical luminal markers compared with conventional vascular proteomic approaches. Our method enables the generation of a high-confidence, compartment-resolved atlas of the luminal cerebrovascular proteome and offers a scalable platform for investigating endothelial surface biology in both healthy and disease contexts.


  • Open Access

    Isolation and Imaging of Microvessels From Brain Tissue

    by Josephine K. Buff, Carolyn R. Bertozzi, Tony Wyss-Coray, Sophia M. Shi

    Proper brain function depends on the integrity of the blood–brain barrier (BBB), which is formed by a specialized network of microvessels in the brain. Reliable isolation of these microvessels is crucial for studying BBB composition and function in both health and disease. Here, we describe a protocol for the mechanical dissociation and density-based separation of microvessels from fresh or frozen human and murine brain tissue. The isolated microvessels retain their molecular integrity and are compatible with downstream applications, including fluorescence imaging and biochemical analyses. This method enables direct comparisons across species and disease states using the same workflow, facilitating translational research on BBB biology.